NKGen Biotech Inc. · OTC:NKGN
NKGen Biotech — SPAC Merger (July 2023)
59 slides from NKGen Biotech's SPAC merger presentation, July 2023
Slide 1: Maximizing Immune Integrity
Maximizing Immune Integrity Investor Presentation July 2023 For Investor Use Only
Slide 2: Disclaimer
Disclaimer Di sclosures This investor presentation (this “Presentation”) has been prepared by NKGen Biotech, Inc. (“NKGen,” “NKGen Biotech” or th e “Company”) for informational purposes only and to assist interested parties in making their own evaluation with respect to the business combination (the
Slide 3: Disclaimer
Disclaimer I mportant Information About the Business Combination and Where to Find I t The proposed Business Combination will be submitted to stockholders of Graf for their consideration. Graf has filed a registration statement on Form S-4, dated May 15, 2023, and amended on June 26, 2023 (as amende
Slide 4: Disclaimer
Disclaimer Fo rward-Looking Statements This Presentation includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial, of Graf and the Company. These statements are based on the beliefs and assumptions of th e management of Graf
Slide 5: NKGen Biotech Is A Clinical Stage Company Focused On Neurodegenerative and Oncological Diseases
NKGen Biotech Is A Clinical Stage Company Focused On Neurodegenerative and Oncological Diseases With Innovative Natural Killer (NK) Cells • Large expansion capacity, • Proposed business • Three Phase I autologous • Clinical/preclinical enhanced cytotoxicity, combination announced SNK01 trials in onc
Slide 6: Executive Team
Executive Team Sangwoo Park* Paul Y. Song, MD* Pierre Gagnon Yong Man Kim, PhD* Founder & Executive CEO and Vice Chairman Chief Operating Officer CIO & Chief Scientific Officer Chairman Founder of NKMAX, NKMAX, Korean Korean Parent Company Parent Company Jack Tsai, MD, MBA Ryan Park, CFA Paul Chang,
Slide 7: Natural Killer Cells
Natural Killer Cells Innate Lymphoid Cells: • 5-15% of circulating lymphocytes Surface Phenotype: • CD3- CD56+ Can Distinguish Non-Self/Dangerous Cells From Healthy Cells: • Ability to kill a broad range of “dangerous” cells • Mediate antibody-dependent cellular cytotoxicity (ADCC) Weak and/or defic
Slide 8: NK Cells Remain Challenging To Grow And Freeze
NK Cells Remain Challenging To Grow And Freeze Problem #1 Problem #2 Problem #3 Problem #4 NK cells Inability to Low Cryopreservation expansion scale up activity limitations production SNK ™ Solution: SNK ™ Solution: SNK ™ Solution: SNK ™ Solution: Consistent >95% pure NK cells Promote high Preserve
Slide 9: State-Of-The-Art GMP Manufacturing Facility
State-Of-The-Art GMP Manufacturing Facility Licensed cell therapy manufacturing facility • 25,000 sq ft facility (12,000 sq ft for GMP) completed in 2019 • CAP/CLIA Laboratory • Facility owned and operated by NKGen Biotech For Investor Use Only 9
Slide 10: SNK01 (Autologous) Superior Expansion, Cytotoxicity, And Activating Receptor Expression
SNK01 (Autologous) Superior Expansion, Cytotoxicity, And Activating Receptor Expression Expansion Fold Expansion Fold NK cell 6000 (8 Healthy Donors) 6000 (11 Cancer Patients) 5060 Expansion 5022 4000 4000 3915 activating FOLD (X) FOLD (X) 3140 receptors and 2000 2000 1096 1100 0 0 ligands D0 D6 D10
Slide 11: NKGen Can Produce Over 100,000 Doses And Maintain High Viability And Cytotoxicity
NKGen Can Produce Over 100,000 Doses And Maintain High Viability And Cytotoxicity Not All Companies Can Produce Large Numbers of Doses And Preserve Viability and Cytotoxicity With Their Cryopreservation Process Whole Blood Drug Release to Viability Cryopreserved Donor selection Collection Substance
Slide 12: NKGen's Differentiated CMC Platform
NKGen’s Differentiated CMC Platform Company with Autologous, Allogeneic, and CAR-NK products Expansion capability demonstrates the potential to produce commercially viable quantities of allogeneic NK cells from a single blood collection –over 100K doses Cryopreservation process that can maintain hig
Slide 13: NKGen Biotech Pipeline
NKGen Biotech Pipeline Product IND Enabling Phase I Phase II Phase III Anticipated Pre-Clinical Clinical Clinical Clinical Milestones • US IND Submission for AD – 2H2023 Monotherapy Neurodegenerative Disease • US IND submission for PD – 1H2024 Autologous SNK01 avelumab or Refractory PD-L1+ and • Fin
Slide 14: Scientific/Clinical Advisors And Collaborators
Scientific/Clinical Advisors And Collaborators Craig Blackstone, MD, PhD Ming Guo, MD, PhD Anthony T. Reder, MD Neurology Advisor Advisor Advisor Yong Ben, MD, MBA Evren Alici, MD, PhD Sant Chawla, MD Oncology Advisor Advisor Collaborator For Investor Use Only 14
Slide 15: Neuro Program
Neuro Program Alzheimer’s and Parkinson’s Diseases For Investor Use Only 15
Slide 16: Market Opportunity in Neurodegenerative Disease
Market Opportunity in Neurodegenerative Disease NKGen’s SNK01, not yet FDA approved, will seek to address a multi-billion/year market Over 55 million people Alzheimer’s We are aware of no therapies worldwide had dementia in and Parkinson’s currently 2020, with a new case patients are estimated to on
Slide 17: Autoreactive T cells Cause Neuroinflammation And Damage
Autoreactive T cells Cause Neuroinflammation And Damage Chronic protein deposition leads to an autoinflammatory cascade and damage Activation of Autoreactive CD4+ and CD8+ T cells1-5 which migrate to the brain via CXCR36 1. Lindestam Arlehamn - NATURE Communications (2020) 11:1875 1-11. 2. Stojić-Vu
Slide 18: NK Cells Regulate Autoreactive T cells
NK Cells Regulate Autoreactive T cells1-4 DNAM-1 CD56 DNAM-1 NKG2D 1. Rabinovich - J Immunol (2003) 170 (7): 3572–3576. 2. Lu - Immunity. 2007 May ; 26(5): 593–604. 3. Nielsen - PLoS ONE 7(2): e31959. 18 For Investor Use Only 4. Ardolino - Blood (2011) 117 (18): 4778–4786.
Slide 19: Autoreactive T cells And SNK01 Cross BBB Via CXCR3
Autoreactive T cells And SNK01 Cross BBB Via CXCR3 CXCR3 Expression CXCR3+ T cells migrate to CXCL10 positive astrocytes that frequently are associated with amyloid deposits. 1 CXCR3 was highly expressed on a subpopulation of neurons and neuronal processes in the neocortex, hippocampus, striatum, ce
Slide 20: Proteins And Damaged Neurons
Proteins And Damaged Neurons NK cells have been found to prevent and reduce protein accumulation1,2 NK cells have also been found to identify and degenerate intact sensory axons after nerve injury3 1. Earls - PNAS - January 2020 117 (3) 1762-1771. 2. Marsh et al. PNAS February 2016 -E1317. 3. Davies
Slide 21: Compassionate Case Study #1 - 38 Y.O. With PSEN1 Mutation And Advanced Alzheimer's
Compassionate Case Study # 1 - 38 Y.O. With PSEN1 Mutation And Advanced Alzheimer’s Treated With SNK01 IMPRESSION: Striking decreased parietal activity with moderate diffuse temporal, occipital and posterior fossa activity. RESULTS AND INTERPRETATIONS: This patient is heterozygous in the PSEN1 gene
Slide 22: Compassionate Use Case Study #2 - 70 Y.O. With Advanced Alzheimer's
Compassionate Use Case Study # 2 – 70 Y.O. With Advanced Alzheimer’s Treated With SNK01 Technical Results: Aβ42 369.1 pg/ml Patient was originally diagnosed in 2016 at Columbia University Medical Center with Advanced Alzheimer’s Disease. T-Tau 692.6 pg/ml P-Tau 83.5 pg/ml ATI 0.35 Patient received 6
Slide 23: Patient Was Granted Single Compassionate Use IND Approval By US FDA
Patient Was Granted Single Compassionate Use IND Approval By US FDA To Resume SNK01 Treatment Patient resumed treatment on 1/27/2023 and has had 3 monthly doses to date at the Neurologic Associates of Long Island Clinic under the care of Dr. Vincent DeOrchis. Currently plan to treat indefinitely unt
Slide 24: Compassionate Case Study #3 - 79 Y.O. With Advanced Alzheimer's
Compassionate Case Study # 3 - Age: 79 Y.O. With Advanced Alzheimer’s Treated With SNK01 Legend MMSE Score Stage ≤12 Severe Dementia Moderate 13-20 Dementia 20-25 Mild Dementia No Cognitive ≥25 Impairment THESE REPORTS OF PATIENT EXPERIENCES AND IMAGES HAVE NOT BEEN VERIFIED OR VALIDATED. ONLY CONTR
Slide 25: Phase I Study Abstract Accepted for the 2023 Alzheimer's Association International Conference
Phase I Study Abstract Accepted for the 2023 Alzheimer’s Association International Phase I Study Conference Abstract in July 2023 Accepted For The 2023 Alzheimer’s Association International Conference (AAIC) In July 2023 No observed SAEs or dose limiting toxicity in this ongoing trial, to date For I
Slide 26: Decreases in Alzheimer's-Related Protein Biomarkers Following SNK01 Treatment
Decreases in Alzheimer’s-Related Protein Biomarkers Following SNK01 Treatment Biomarker Interim Data1 From MX04 Phase I Trial2 pTau 181 Change At Week 11 from the baseline At Week 11 Aβ 42 Change from the baseline 50% had improved levels3 90% had improved or stable levels 70% had improved levels Wor
Slide 27: Dose Response From Baseline Following SNK01 Treatment
Dose Response From Baseline Following SNK01 Treatment Biomarker Interim Data From MX04 Phase I Trial Worsening Worsening 1 WEEK AFTER THE LAST 12 WEEKS AFTER 1 WEEK AFTER THE LAST 12 WEEKS AFTER DOSE THE LAST DOSE DOSE THE LAST DOSE For Investor Use Only 27
Slide 28: Tau > Amyloid?
Tau > Amyloid? Clinical pathological studies have linked tau pathology closely to the onset and progression of cognitive symptoms in patients with Alzheimer's disease1-3 Tau proteins , not amyloid, may be a key driver of Alzheimer's symptoms as accumulation of tau in the brain can predict cognitive
Slide 29: Decreases In Alzheimer's-Related Inflammatory Markers Following SNK01 Treatment
Decreases In Alzheimer’s-Related Inflammatory Markers Following SNK01 Treatment Biomarker Interim Data From MX04 Phase I Trial YKL-40 Change At Week 11 G FAP Change At Week 11 f rom the baseline f rom the baseline 60% had improved levels 60% had improved or stable levels 50% improved Neuroinflammati
Slide 30: Dose Response From Baseline Following SNK01 Treatment
Dose Response From Baseline Following SNK01 Treatment Biomarker Interim Data From MX04 Phase I Trial Decrease in AD Patient Neuroinflammation 1 WEEK AFTER THE LAST 12 WEEKS AFTER 1 WEEK AFTER THE LAST 12 WEEKS AFTER DOSE THE LAST DOSE DOSE THE LAST DOSE For Investor Use Only 30
Slide 31: Changes In Cognitive Function Following SNK01 Treatment
Changes In Cognitive Function Following SNK01 Treatment Interim Data From MX04 Phase I Trial Worsening Worsening Worsening were stable or improved were stable or improved were stable or improved 60% one week after final dose 70% one week after final dose 50% one week after final dose remained stable
Slide 32: Dose Response From Baseline Following SNK01 Treatment
Dose Response From Baseline Following SNK01 Treatment Cognitive Function Interim Data From MX04 Phase I Trial Worsening Worsening Worsening 1 WEEK AFTER THE LAST 12 WEEKS AFTER 1 WEEK AFTER THE LAST 12 WEEKS AFTER 1 WEEK AFTER THE LAST 12 WEEKS AFTER DOSE THE LAST DOSE DOSE THE LAST DOSE DOSE THE LA
Slide 33: Parkinson's Compassionate Use Case Study
Parkinson’s Compassionate Use Case Study # 1 : Qualitative Evaluation Of 47 Y.O. After Treatment with SNK01 Patient was independently seen and evaluated by Dr. Ming Guo (at UCLA Medical Center) 60% Mental sharpness/reaction 50% Fatigue/energy Percent Improvement from Baseline Speech 40% Left Leg Mov
Slide 34: Oncology Program
Oncology Program For Investor Use Only 34
Slide 35: Improved Survival Rates Following SNK01 Combination Treatment with a PD-1 Inhibitor
Improved Survival Rates Following SNK01 Combination Treatment with a PD-1 Inhibitor Pembrolizumab Pembrolizumab + SNK Pembrolizumab Pembrolizumab + #5 SNK #5 2-Year PFS 2-Year Survival SNK01 + pembrolizumab 25% 58.3% Pembrolizumab Pembrolizumab + Pembrolizumab monotherapy 0% 16.7% SNK #5 Synergistic
Slide 36: Can SNK Change The TME For PDL1- Tumors?
Can SNK Change The TME For PDL1- Tumors? NK cells can positively affect the TME to help make PD-L1 negative tumors respond to ICIs* Patient Age: 321 • Stage IVB Desmoplastic Small Round Cell Sarcoma • Diagnosed 2017 • Disease included lung, abdomen and pelvis with extensive disease in abdominal/ pel
Slide 37: Effect Of NK Cells On Cetuximab-mediated ADCC
Effect Of NK Cells On Cetuximab-mediated ADCC Preliminary Phase I data Presented at ASCO 2023 Media IgG EGFR A B * ** *** 100 *** *** *** * 80 *** * ** 80 ** 60 Lysis (%) 60 Lysis (%) 40 40 20 20 0 0 Con GC Con GC Con GC Con GC Con GC Con GC parental PC-9 PC-9/GR PC-9/OR parental HCC827 HCC827/GR HC
Slide 38: ASCO 2023 Poster Presentation SNK01 Phase I/IIa Clinical Trial Results
ASCO 2023 Poster Presentation SNK01 Phase I/IIa Clinical Trial Results ClinicalTrials.gov Identifier: NCT04872634 12 patients with TKI resistant metastatic NSCLC were evaluated Dose-limiting toxicity was not observed, therefore the maximum tolerated dose of SNK01 was determined to be 6×109 cells/dos
Slide 39: NK Cells: The Missing Piece In Cancer Therapeutics?
NK Cells: The Missing Piece In Cancer Therapeutics? Tumor targeting Immune activation Immune effectors We believe that the future of cancer therapies will be in mAbs, ADCs PD-1/L1, CTLA-4, TIGIT Missing piece: Adoptive, combination therapies that enhanced NK effector cells enable precision targeting
Slide 40: Why NKGen? Overcoming industry challenges
Why NKGen? Limited ex-vivo expansion Critical Issue NK Cell Expansion >100K doses from single peripheral blood draw Industry Challenge NKGen Solution Low activity at baseline, complex Limited NK product offerings engineering Product Flexibility Cytotoxicity Company with autologous, Highly enhanced c
Slide 41: Transaction Overview
Transaction Overview1 Key transaction Terms • ~$161M transaction equity value2 • 100% equity rollover • $50M minimum net cash closing condition3 • Proceeds expected to fund trials and operations into 20254 • $25M backstop commitment from majority shareholder5 • Expected closing in Q3 2023 • Potentia
Slide 42: Thank you
Thank you For Investor Use Only
Slide 43: Appendix
Appendix For Investor Use Only 43
Slide 44: US Phase I Allogeneic Trial Expected To Begin In 2H2023
US Phase I Allogeneic Trial Expected To Begin In 2H2023 Allogeneic NK cell product that does not require lymphodepletion. Confidential For Investor Use Only 44
Slide 45: Autologous Next Gen Manufacturing
Autologous Next Gen Manufacturing NKGen “Off-the-Shelf Autologous” SNK Cell Therapy Superior Cell Our Expansion and Cryoprocess Activation preserves cell features Auto-SNK No Lymphodepletion 1 2 3 5 4 5 Collect Isolate Activate & Expand Cryopreserve Deliver to Clinic Thaw and Administer Leukapheresi
Slide 46: Intellectual Property
Intellectual Property NK Cell Expansion Platform Patents Patent Family 1 Patent Family 2 Additional Patent Families • Cryopreservation and recovery of highly • Highly cytotoxic NK Cells • Larger yields -- ideal for allogeneic production cytotoxic NK cells • Consistently large yields (including unhea
Slide 47: Cash Used in Operating Activities
Cash Used in Operating Activities NKGen expenses 2020 2021 2022 Total cash burn1 $17.3M $19.9M $22.5M RND-only cash expenses2 $10.6M $14.0M $15.7M 1. Total cash burn amount equals net cash used in operating activities, which is a GAAP financial measure. 2. R&D-only cash expenses represent R&D expens
Slide 48: Significant Opportunity With Funding Potential From Partnering Our Platform And In Oncology
Significant Opportunity With Funding Potential From Partnering Our Platform And In Oncology Autologous SNK for Autologous SNK for NK cells for CDMO for NK Cellular Parkinson's Alzheimer’s Oncology Processes Demonstrate safety and Demonstrate safety and SNK01 proof of concept in Superior manufacturin
Slide 49: Allogeneic Anti-HER2-CAR SNK02
Allogeneic Anti-HER2-CAR SNK02 (US IND submission anticipated in 2025) For Investor Use Only 49 CONFIDENTIAL
Slide 50: NKGen – Engineering, Expansion, And Cryopreservation
NKGen – Engineering, Expansion, And Cryopreservation Analysis / NK cell Expansion & Collection Engineering Collection Final product stimulation Enrichment and cell banking IL-2 IL-21 Feeder D0 D3-6 D10-11 D14 D45 For Investor Use Only 50
Slide 51: Expression Level Of Anti-HER2-CAR on NK Cell
Expression Level Of Anti-HER2-CAR on NK Cell CAR Expression 100 89.03 85.67 87.93 86.31 87.16 86.03 90 83.03 81.62 82.74 80 70 % expression 60 50 40 SNK anti-HER2-CAR NK 30 20 10 1.11 1.05 2.3 2.47 2.39 1.89 2.42 1.38 1.64 0 D10 D14 S1 D6 S1 D10 S1 D14 S2 D6 S2 D10 S2 D14 S2 D17 Promoter leader Hing
Slide 52: NK Cell Expansion Rate
NK Cell Expansion Rate E xpansion R at e ( P1 ) E xpansion R at e ( S1 ) E xpansion R at e ( S2) 450 1200 3000 SNK SNK SNK 400 1000 2500 Expansion fold 350 Anti-HER2-CAR SNK Anti-HER2-CAR-SNK anti-HER2-CAR SNK 300 800 2000 250 SNK: 427.8-fold SNK: 1012.4-fold SNK: 2489.5-fold 600 1500 200 CAR SNK: 3
Slide 53: The Effect Of Freezing/Thawing On CAR Expression & Cytotoxicity
The Effect Of Freezing/Thawing On CAR Expression & Cytotoxicity CAR Expression Cytotoxicity (2 hours) Fresh (SK-OV3) Thawing ( SK - O V3) 50 SNK02 SNK02 80 Anti-HER2-CAR 40 Anti-HER2-CAR SK-OV3 SNK02 SNK02 60 30 Persistence 40 20 100 20 10 86.03 83.2 82.84 84.02 90 81.6 0 0 80 1 0:1 5:1 2.5:1 1 .25
Slide 54: Partnerships With Merck And Pfizer
Partnerships With Merck And Pfizer In September 2020, NKGen (formerly NKMax America) entered into a clinical trial collaboration and supply agreement with Germany-based Merck KGaA to evaluate the safety and tolerability of SNK01, NKGen's autologous NK cell therapy in combination with avelumab (BAVEN
Slide 55: SNK01 – MX04 Phase I Trial
SNK01 – MX04 Phase I Trial Dosing and Administration: To identify the Maximum Tolerated Dose (MTD), the subjects were given SNK01 in an open-label setting per the following treatment plan, using a 3 + 3 design: • Cohort 1 - 1.0 x 109 cells; infusions Q3W, total of four doses. • Cohort 2 - 2.0 x 109
Slide 56: References For NK Cells And PD-1/PD-L1
References For NK Cells And PD-1/PD-L1 • Hasim, M., et al. (2022). When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer. ScienceAdvances, 8(15). • Hsu, J., et al. (2018). Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest, 128(10):4654-4668
Slide 57: References For CI Tolerability
References For CI Tolerability • Trinh, S., et al. (2019). Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines. Asia Pac J Oncol Nurs, 6(2):154-160. • Berti, A., et al. (2021). Meta-analysis of immune-related ad
Slide 58: References For Neurodegenerative Disease
References For Neurodegenerative Disease • Zhou, Y-Q, et al. (2019). The role of CXCR3 in Neurological Diseases. Curr Neuropharmacol, 17(2): 142-150. • Marsh, S.E., et al. (2016). The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc Natl Acad
Slide 59: References Neurodegenerative Disease (Cont.)
References Neurodegenerative Disease (Cont.) • Earls, R.H., et al., (2020). NK cells clear alpha-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of alpha- synucleinopathy. Proc Natl Acad Sci U S A, 117(3):1762-1771. • Rabinovich, B.A., et al. (2003). Activate